GAMMADELTA THERAPEUTICS LTD has a total of 23 patent applications. Its first patent ever was published in 2018. It filed its patents most often in United Kingdom, WIPO (World Intellectual Property Organization) and Australia. Its main competitors in its focus markets biotechnology and pharmaceuticals are FINNISH NAT PUBLIC HEALTH, SHENZHEN BINDE BIOTECHNOLOGY CO LTD and PLUECKTHUN ANDREAS.
# | Country | Total Patents | |
---|---|---|---|
#1 | United Kingdom | 9 | |
#2 | WIPO (World Intellectual Property Organization) | 6 | |
#3 | Australia | 3 | |
#4 | Brazil | 1 | |
#5 | Canada | 1 | |
#6 | EPO (European Patent Office) | 1 | |
#7 | Israel | 1 | |
#8 | United States | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals |
# | Technology | |
---|---|---|
#1 | Microorganisms | |
#2 | Peptides | |
#3 | Medical preparations | |
#4 | Therapeutic chemical compounds |
# | Name | Total Patents |
---|---|---|
#1 | Nussbaumer Oliver | 11 |
#2 | Mehta Raj | 6 |
#3 | Pizzitola Irene | 5 |
#4 | Kovacs Istvan | 4 |
#5 | Polyakova Oxana | 4 |
#6 | Mount Natalie | 3 |
#7 | Uden Mark | 3 |
#8 | Hutton Andrew | 2 |
#9 | Soderstrom Kalle | 2 |
#10 | Hayday Adrian | 2 |
Publication | Filing date | Title |
---|---|---|
GB202102222D0 | Multispecific anti-TCR delta variable 1 antibodies | |
GB202013962D0 | Immunotherapy composition | |
WO2021032961A1 | Ex vivo gamma delta t cell populations | |
WO2021032963A1 | Therapeutic uses of anti-tcr delta variable 1 antibodies | |
GB202012172D0 | Gamma delta cell populations | |
GB202010760D0 | Novel antibodies | |
GB202002581D0 | Novel antibodies | |
WO2020095058A1 | Methods for isolating and expanding cells | |
GB201911798D0 | Novel antibodies | |
GB201911799D0 | Novel Antibodies | |
GB201818243D0 | Methods for isolating and expanding cells | |
GB201804701D0 | Lymphocytes expressing heterologous targeting constructs |